~ Agreement grants VectorY the exclusive right to evaluate and license Shape’s non-invasive, deep-brain penetrating AAV5-derived capsid for vectorized antibodies against three targets ~ ~ License will ...
Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the unveiling of the AAVid TM capsid discovery ...
CHAMPAIGN, Ill. — Researchers report that they have determined the precise chemical structure of the HIV capsid, a protein shell that protects the virus's genetic material and is a key to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback